The product, Crunch, doesn’t have any carrier or filler additives and is designed to resist washing away or straying from surgical sites, according to a July 19 news release.
“Our newly launched crunch contains cancellous bone fragments within the crunch to provide the osteoconductive scaffolding to promote new bone growth,” Ossifix CEO Mark Estrada said in the release. “Healthcare practitioners can choose to add fresh marrow aspirate or allograft from the patient to promote further osteogenesis.”
Ossifix is a subsidiary of Umbra Applied Technologies Group and is based in Austin.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
